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Abstract
Spastic paraplegia 7 is an autosomal recessive disorder caused by mutations in the gene encoding paraplegin, a protein
located at the inner mitochondrial membrane and involved in the processing of other mitochondrial proteins. The
mechanism whereby paraplegin mutations cause disease is unknown. We studied two female and two male adult patients
from two Norwegian families with a combination of progressive external ophthalmoplegia and spastic paraplegia.
Sequencing of SPG7 revealed a novel missense mutation, c.2102A.C, p.H 701P, which was homozygous in one family and
compound heterozygous in trans with a known pathogenic mutation c.1454_1462del in the other. Muscle was examined
from an additional, unrelated adult female patient with a similar phenotype caused by a homozygous c.1047insC mutation
in SPG7. Immunohistochemical studies in skeletal muscle showed mosaic deficiency predominantly affecting respiratory
complex I, but also complexes III and IV. Molecular studies in single, microdissected fibres showed multiple mitochondrial
DNA deletions segregating at high levels (38–97%) in respiratory deficient fibres. Our findings demonstrate for the first time
that paraplegin mutations cause accumulation of mitochondrial DNA damage and multiple respiratory chain deficiencies.
While paraplegin is not known to be directly associated with the mitochondrial nucleoid, it is known to process other
mitochondrial proteins and it is possible therefore that paraplegin mutations lead to mitochondrial DNA deletions by
impairing proteins involved in the homeostasis of the mitochondrial genome. These studies increase our understanding of
the molecular pathogenesis of SPG7 mutations and suggest that SPG7 testing should be included in the diagnostic workup
of autosomal recessive, progressive external ophthalmoplegia, especially if spasticity is present.
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Introduction
The hereditary spastic paraplegias (HSP) are clinically and
genetically heterogeneous disorders characterized by the triad of
progressive spastic paraparesis, hyperactive bladder and mild
sensory dysfunction in the lower limbs [1–4]. Additional features
include cerebellar ataxia, peripheral neuropathy, amyotrophy,
extrapyramidal symptoms, cognitive impairment, deafness and
visual impairment [1]. To date, over 50 loci have been mapped
[5–7] and at least 25 genes identified, encoding proteins with a
variety of functions including intracellular trafficking, mitochon-
drial metabolism and myelinization [8].
Spastic paraplegia 7 (SPG7) is an autosomal recessive disease
caused by mutations in SPG7 encoding the protein paraplegin.
Paraplegin is a member of the AAA family of ATPases and
contains both metallopeptidase and ATPase domains. It is located
at the inner mitochondrial membrane and involved in processing
mitochondrial proteins [9] and the assembly of the mitochondrial
ribosome [10].
Over 50 pathogenic SPG7 mutations have been reported
including point mutations and large deletions affecting most of
its 17 exons: missense mutations are the most frequent subgroup
[11]. The prevalence of paraplegin mutations in sporadic or
autosomal recessive HSP index cases ranges from 1.5% [12] to
around 12% [6,13–15].
Phenotypically, SPG7 is often a pure HSP, but cerebellar
dysfunction and cerebellar atrophy on MRI are common
[12,16,17]. Additional findings include upper limb hyperreflexia,
sphincter dysfunction, spastic dysarthria, optical neuropathy,
nystagmus, strabismus, decreased hearing, scoliosis, pes cavus,
motor and sensory neuropathy, amyotrophy, blepharoptosis and
ophthalmoplegia (Table 1) [1,4,12,14–16,18–22]. Onset is usually
in adulthood, but ranges between 10–72 years [13,16,18,21].
The molecular pathomechanism of SPG7 mutations remains
unknown. Studies in skeletal muscle have shown evidence of
mitochondrial respiratory chain (MRC) dysfunction in the form of
cytochrome oxidase (COX) negative muscle fibers [13,21,23,24] in
some cases while another found none [16]. Fibroblast studies have
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shown evidence of reduced complex-I activity in some, but not in
all patients tested [24,25].
We identified a novel SPG7 mutation in two Norwegian families
presenting with ptosis and progressive external ophthalmoplegia
(PEO) in addition to spastic paraparesis. Studies of the muscle
mitochondrial DNA (mtDNA) showed evidence of multiple
deletions, thus providing an explanation for the respiratory chain
dysfunction often identified in this tissue and linking paraplegin to
mtDNA homeostasis.
Materials and Methods
Ethics
Our study was approved by the Regional Committee for
Medical and Health Research Ethics, South-Eastern Norway
(ethical agreement nu129/04011). Written informed consent was
obtained from all study participants.
Patients
We studied two families (A and B), each with two affected
siblings, from south eastern Norway. Muscle biopsy was available
from an additional patient (CII-5) whose clinical and genetic
features have been previously described [20].
In Family A, the parents were first cousins, whereas in family B
there was no known consanguinity (Figure 1). All patients
underwent neurological examination according to a standard
protocol that included Spastic Paraplegia Rating Scale (SPRS) and
Scale for the Assessment and Rating of Ataxia (SARA) [26,27].
Weakness was graded according to Medical Research Council
(MRC) Scale for Muscle Strength. MRI, electrophysiological
investigations and Intelligence Quotient (IQ) testing were
performed in the index patients of the two families (Patients
AIV-5 and BIII-2). IQ assessment was also done in patient BIII-5.
Muscle biopsy was performed in patients AIV-5 and CII-5.
Genetic Analyses
Genomic DNA was extracted from peripheral blood of patients
and controls using standard techniques. Sequencing of POLG1,
POLG2 and C10orf2 were performed in patient AIV-5. Sanger
sequencing of the complete coding region of SPG7 and MLPA
(Multiplex Ligation-dependent Probe Amplification) analysis were
performed in patient AIV-5 by Stichting Klinisch-Genetisch
Centrum, Nijmegen, The Netherlands, using standard methods.
Targeted mutation analysis was performed by Sanger sequencing
in all patients and 192 controls (Table S1). Sequencing was done
in an ABI 37306l DNA analyzer (Life Technologies Corporation,
Carlsbad, California) using ABI BigDye dye terminator cycle-
sequencing kits (Life Technologies Corporation). Alignment of
patients and controls sequences versus the February 2009 human
reference sequence (GRCh37) was obtained using Mega software
(http://www.megasoftware.net/mega4/mega.html) [28].
Table 1. Summary of the clinical features of four SPG 7 patients.
Earlier studies Patient AIV-5 Patient AIV-2 Patient BIII-2 Patient BIII-5
Age at onset 10–72 years 7 years 8 years 15 years 27 years
Age at examination 67 years 63 years 69 years 67 years
Ptosis + + + + +
Progressive external ophthalmoplegia + + + + +
Dysarthria Spastic/cerebellar Spastic Spastic Cerebellar Cerebellar
Retinopathy + Pigmentation and
atrophy
NA – NA
Dystonia + – – – –
Cerebellar atrophy yes yes yes yes NA
Upper limb hyperreflexia + + + + +
Upper limb spasticity + + + + –
Upper limb weakness + MRC 4 MRC 4 MRC 5 MRC 5
Lower limb hyperreflexia + + + + +
Lower limb spasticity + + + + +
Lower limb weakness + MRC 1–2 MRC 1–2 MRC 3–4 MRC 3–4
Plantar response inversion + + + + +
Limb ataxia + + + + +
Truncal ataxia + + + + +
Urge incontinence + + + + +
Decreased vibratory sense + + + + +
Nystagmus + – – + +
Cognitive impairment + + NA + +
Dysphagia + – NA – –
Decreased hearing + – – + –
Pes cavus + – – + –
Amyotrophy + + + – –
doi:10.1371/journal.pone.0086340.t001
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Expression Studies
RNA was extracted from blood of patient AIV-5 and controls
using a commercial kit (RNeasy Mini Kit, Qiagen) and converted
to cDNA using High Capacity cDNA Reverse Transcription Kit
(Life Technologies Corporation). In order to assess splice effects,
cDNA from the patient and two controls was used to amplify
exons flanking the mutation (Table S1). PCR products were
subsequently run on an 1.5% agarose gel, Sanger sequenced and
aligned using Mega software. SPG7 expression was assessed in
blood leukocytes of patient AIV-5 and seven healthy controls by
real time-PCR (RT-PCR) using SYBR Green JumpStart Taq
ReadyMix chemistry (Sigma-Aldrich, Saint Louis, MO) and
primers targeting SPG7 cDNA (Table S1). Reactions were run
in triplicate on the ABI Real Time PCR 7900 HT Sequence
Detector System (Life Technologies Corporation) and amplifica-
tion levels were calculated as previously described [29]. Primers
were designed using Primer 3 (http://frodo.wi.mit.edu/) [30].
In silico Analyses
Conservation score for the mutated DNA base was evaluated
using PhastCons and Genomic Evolutionary Rate Profiling
(GERP) software available at the University of California Santa
Cruz [31,32]. Positive scores represent a substitution deficit and
thus indicate that a site may be under evolutionary constraint.
Negative scores indicate that a site is probably evolving neutrally.
Potential effects of the point mutation on protein structure and
function was evaluated using the prediction softwares SIFT
(Sorting Intolerant From Tolerant; http://sift.jcvi.org/www/
SIFT_intersect_coding_submit.html) [33] and PolyPhen-2 (Poly-
morphism Phenotyping v2; (http://genetics.bwh.harvard.edu/
pph2/) [34,35].
Muscle Biopsy
Open muscle biopsy was performed from the vastus lateralis
muscle of patients AIV-5 at the age of 67 and CII-5 at the age of
43 years. The muscle sample was snap-frozen in isopentane cooled
in liquid nitrogen and stored at 280oC. The muscle biopsies of a
patient with a single mtDNA deletion (SD), a patient with multiple
mtDNA deletions due to POLG mutations (MD) and 10 individuals
with no mitochondrial or neuromuscular disease and a mean age
of 37.1616.5 years (range 18–62) at the time of the biopsy were
used as controls.
Histochemistry & Immunohistochemistry
Histological and histochemical studies were performed in the
muscle of patient AIV-5, the two disease controls (MD, SD) and all
healthy controls (n = 10). Serial 8 mm frozen sections were cut, air
Figure 1. Pedigree of families A and B.
doi:10.1371/journal.pone.0086340.g001
Figure 2. Brain MRI of patient AIV-5 showing cerebellar
atrophy.
doi:10.1371/journal.pone.0086340.g002
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dried for 1 hour and stained with histochemical (HC) and
immunohistochemical (IHC) methods. Sequential histochemical
assay of cytochrome oxidase (COX) and succinate dehydrogenase
(SDH) activity was performed as previously described [36]. For
immunohistochemistry the sections were fixed for 15 min in cold
acetone (4oC), rinsed in distilled water, washed in Tris-buffered
saline (TBS) containing 0.1% Tween 20 (TBST) for 10 min,
permeabilised in a graded methanol series containing hydrogen
peroxide to inhibit endogenous peroxidase activity, washed in
TBST for 5 min and incubated in optimal concentrations of
primary antibodies for 1 hour at room temperature. Primary
antibody binding was detected with a commercial kit (MACH 4
Universal HRP-Polymer Kit with DAB, Biocare Medical).
Sections were washed in 2 changes of TBS for 5 min, incubated
with a universal probe recognizing mouse and rabbit primary
antibodies for 30 min, washed in 2 changes of TBS and incubated
in a horseradish peroxidase (HRP) polymer for 30 min at room
temperature. Sections were then washed in 3 changes of TBS for
5 min and visualized with 3,3-diaminobenzadine (DAB), counter-
stained in Mayer hematoxylin (Sigma Aldrich) for 15 sec, and the
nuclei were blued in Scott tap water (Sigma Aldrich). Section
analysis and cell counts were performed on a Leica light
microscope (Leica Microsystems, GmbHWetzlar, Germany) using
Zeiss ZEN imaging software. Primary antibodies were used against
respiratory complex-I 20 kDa subunit (NDUFB8) (diluted 1:100),
complex-II 70 kDa subunit (SDHA) (1:1000), complex-III core-2
protein subunit (UQCRC2) (1:500), complex-IV subunit CO1
(1:400) and porin subunit VDAC1 (1:2000). All antibodies were
purchased from Abcam. The degree of complex deficiencies in
skeletal muscle is expressed as a proportion of unstained (negative)
fibres.
MtDNA Studies
MtDNA studies were performed in muscle homogenate DNA of
patients AIV-5 and CII-5, the two disease controls with single (SD)
and multiple (MD) mtDNA deletions and the 10 healthy controls.
Single fibre studies were performed in patient AIV-5, the two
disease controls (MD, SD) and three healthy controls aged 26, 38
and 57 years at the time of the biopsy. Genomic DNA was
extracted from muscle biopsy homogenate using a commercial kit
(QIAamp DNAMini Kit, Qiagen). Single muscle fibres were laser-
microdissected from 20 mm frozen sections stained with COX/
SDH histochemistry using a PALM microdissection microscope
(Zeiss). Individual muscle fibres were lysed overnight in 15 ml of
lysis buffer as previously described [37]. MtDNA deletions were
detected in DNA from muscle homogenate using long-range PCR
(LPCR) to amplify an 8.3 kb (8232–16496) fragment as previously
described [38]. Quantification of total and deleted mtDNA was
performed in muscle homogenate and single fibre lysates using
real-time PCR to compare amplification within a rarely deleted
area (MT-ND1) to that of a commonly deleted area (MT-ND4) as
previously described [37,39].
Results
Case Reports
The clinical features of the patients are summarized in Table 1.
Family A. Subject AIV-5 (index). This man who is currently 67
years of age, developed progressive problems with coordination of
Figure 3. Immunohistochemistry in serial sections of the muscle of patient AIV-5. Immunohistochemistry for complex I (A), complex II (B),
complex III (C) and COX/SDH histochemistry (D) in serial sections of the muscle of patient AIV-5. There are complex I, III and IV deficient fibres, but
complex I deficiency is most pronounced. Arrows mark serial sections of the same muscle fibers stained for different complexes.
doi:10.1371/journal.pone.0086340.g003
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upper and lower limbs and lower limb stiffness from the age of
seven years. He walked with a stick from the age of 25 years and
became wheelchair bound aged 39. Neurological examination at
the age of two years, following a minor head injury, was
unremarkable with the exception of a unilateral extensor plantar
response. Examination at the age of 22 years after a traffic
accident revealed failure of abduction of the left eye, hyperreflexia
in all four extremities and Babinski sign. Follow-up at the age of 40
years revealed severe spastic paraparesis with bilateral Babinski
sign, and in the upper limbs moderate weakness and hyperreflexia
was present. There was bilateral ptosis and partial conjugate gaze
palsy in all directions. He had symptoms of a neurogenic bladder,
without incontinence. Electroencephalography (EEG), electromy-
ography (EMG) and nerve conduction velocities (NCV) were
normal.
Figure 4. MtDNA studies in the muscle of two SPG7 patients and controls.MtDNA studies in the muscle of two SPG7 patients (AIV-5 and CII-
2) and controls. Results from a patient with a single mtDNA deletion (SD) and a patient with multiple mtDNA deletions due to POLG mutations (MD)
are also shown for comparison. A: LPCR of mtDNA shows multiple deletions in the two SPG7 patients. The ladder is 1 kb (GeneRuler). B: blank. B: qPCR
of mtDNA in muscle homogenate shows no detectable deletions (ND4/ND1 ratio within the control range) in the SPG7 patients. Low ND4/ND1 ratios
consistent with ,60% and ,50% deleted mtDNA are found in the patients with single and multiple mtDNA deletions respectively. Error bars mark
standard deviations. C: Scatter plot showing the proportion of deleted mtDNA in microdissected COX-positive and COX-negative muscle fibres from
an SPG7 patient (AIV-5) and a patient with single mtDNA deletion. Deletions reach significantly higher levels (38–97%) in the COX-negative, than in
the COX-positive fibres (0–7%) of the SPG7 patient. No deletions are detected in single fibres from three healthy controls. Each dot represents data
from a single fibre. COX: cytochrome-oxidase. *P = 0.008 (comparison by Mann-Whitney test).
doi:10.1371/journal.pone.0086340.g004
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Clinical examination by the authors at the age of 67 years
showed a marked spastic paraparesis with severe muscle weakness.
Moderate truncal ataxia was present with bilateral dysmetria and
dysdiadochokinesia. It was not possible to assess cerebellar
function in the legs due to weakness. There was a mild impairment
of vibration sense at the ankles, otherwise proprioception,
temperature and superficial sensation to touch and pin prick was
normal. SARA-score was 29/40, and SPRS-score 43/52.
Ophthalmological examination showed a nearly complete
external ophthalmoplegia with diminished oculocephalic reflex
and severe ptosis with significant narrowing of the palpebral
fissures (,4 mm) as well as continuous activation of the frontal
muscle. There was increased retinal pigmentation of the right eye
and paramacular atrophy in the left. Visual acuity was 0.4–0.6.
Cognitive assessment with full scale 2-subtest Wechsler’s abbrevi-
ated scale of intelligence (WASI) [40] was suggestive of cognitive
impairment with full IQ of 79, of which his verbal IQ was
equivalent with the 32nd percentile, and his executive IQ with the
41st percentile. MRI of the brain revealed cerebellar atrophy and
mild atrophy of the corpus callosum (Figure 2), whereas MRI of
the spine and cord was normal. NCV showed a mixed, but
primarily axonal sensorimotor peripheral neuropathy with low
sensory amplitudes and normal conduction speed, and low motor
amplitudes and delayed conduction speed. EMG showed a slight
decrease in the recruitment pattern. Serum creatine kinase (CK)
levels were normal.
Subject AIV-2. This 64-year old female developed progressive
unsteadiness from the age of eight years. She experienced leg
stiffness, but poor coordination and unsteadiness were her main
complaints. Subsequently, she developed urge incontinence and
mild dysarthria. She became wheelchair bound from the age of 43
years. Examination at the age of 63 years showed severe cerebellar
ataxia in truncus and extremities. There was hyperreflexia in both
upper and lower limbs and spastic paraplegia with a bilateral
Babinski sign. She had external ophthalmoplegia with impaired
vertical eye motility, slow horizontal saccades and impaired slow
pursuit. In addition there was a moderate bilateral ptosis with the
palpebral aperture measuring 5 mm [41]. Serum creatine kinase
(CK) levels were normal.
Subjects AIV-1 and AIV-3 had no symptoms and normal
neurological examination.
Family B. Subject BIII-2 (index). This 69 year old woman
developed weakness in the left leg at the age of 15. From the age of
30 she developed progressive unsteadiness and lower limb stiffness
followed by urinary urge incontinence. She underwent bilateral
blepharoptosis surgery at the age of 61. Examination at the age of
62 showed spastic paraparesis, with retained ability to walk short
distances with a walker. There were subtle cerebellar signs in the
upper limbs and mild cerebellar dysarthria. Ophthalmological
examination showed normal retinal and macular findings, but
visual acuity was 0.3–0.5. MRI of the brain showed severe
cerebellar atrophy, especially affecting the vermis. MRI of the
spine and cord was normal.
Follow-up examination at the age of 69 revealed mild worsening
of the spastic paraplegia.
SARA-score was 26/40, and SPRS-score 45/52. There was a
moderate external ophthalmoplegia with reduced oculocephalic
reflex and a severe ptosis with significant narrowing of the
palpebral fissures (.4 mm). Cognitive assessment with full scale 2-
subtest WASI was suggestive of cognitive impairment with full IQ
of 78, of which her verbal IQ was equivalent with the 27th
percentile, and her executive IQ with the 44th percentile.
Subject BIII-5. This man developed progressive gait unsteadiness
from the age of 27 years. He lost unsupported gait in his mid-
thirties, but is still able to walk with the aid of two sticks at the age
of 67. Examination at the age of 67 revealed spastic paraparesis,
dysarthria and mild upper limb ataxia. There was a mild
impairment of vibration sense, but proprioception and superficial
sensation were normal. He had bilateral ptosis with the palpebral
aperture measuring 5 mm and external ophthalmoplegia which
was complete for vertical gaze and moderate for horizontal
movements. In addition, horizontal gaze showed slow saccades
and saccadic smooth pursuit.
Cognitive assessment with 2-subtest WASI showed IQ 78, of
which his verbal IQ was equivalent with the 30th and his executive
IQ with the 41st percentile.
Family C. The clinical and genetic features of subject CII-5
have been previously described [20].
Muscle Biopsy
Routine muscle histology in the index patient of family A
(Patient AIV-5) showed no ragged red fibres and was otherwise
normal. IHC and HC showed deficiency of the respiratory
complexes I (4.5%), III (3.5%) and IV (3.3%). Complex II and
porin stained all fibres and no defects were seen in control muscle
(Figure 3). Multiple complex deficiencies co-localized in the same
fibres, but complex I loss was more widespread. Electron
microscopy showed increased amount of fat vacuoles within the
muscle fibres and was otherwise normal.
Genetic Analyses
A novel homozygous point mutation c.2102A.C in SPG7
(NM_003119.2) was found in the two affected siblings of family A
and was heterozygous in unaffected subjects AIV-1 and AIV-3.
The mutation segregated in the families and was absent in 384
chromosomes from 192 ethnic Norwegian controls. This is a
missense mutation changing a highly conserved histidine in
position 701 to a proline (p.H 701P) in the Pfam Peptidase
domain (http://smart.embl-heidelberg.de/) of the protein (Figure
S1). The mutation is located at the donor splicing site of exon 15,
but amplification and sequencing of a cDNA segment spanning
exons 13–17 showed no evidence of aberrant splicing (Figure S2).
Real-time PCR analysis of cDNA from blood of patient AIV-5 did
not detect significant differences in SPG7 expression in the patient
compared to seven healthy controls (Figure S2).
In silico analysis of the mutation by PolyPhen-2 predicted no
effects on protein stability with a score of 0.260 (sensitivity: 0.91;
specificity: 0.88). SIFT prediction of the mutation also indicates
the mutation to be tolerated with a SIFT-score of 0.21 and a
median of 2.57.
In family B the same mutation was found compound
heterozygous in trans, with the earlier described pathogenic in
frame deletion c.1454_1462 (pArg485_Glu487del) [21].
Sequencing of POLG1, POLG2 and C10orf2 was normal in
patient AIV-5.
MtDNA Studies in Muscle
Long-range polymerase chain reaction (LPCR) in muscle
homogenate DNA showed a normal sized band at 8 kb together
with several smaller bands consistent with the presence of multiple
mtDNA deletions in both SPG7 patients examined (Figure 4A).
No deletions were detected in muscle homogenate by real-time
PCR which showed a normal ND4/ND1 ratio (Figure 4B). Single
fibre analysis in patient AIV-5 showed that deleted mtDNA species
segregated at significantly (p=0.008) higher levels (38–97%) in
COX-negative fibres than in in COX-positive fibres where they
were absent or present at very low levels (0–7%). No deletions
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were detected in single fibres from three healthy controls
(Figure 4C).
MtDNA quantification against the APP gene showed no
significant changes in mtDNA content in the muscle of the
patients compared to the mean of 10 healthy controls (data not
shown).
Discussion
Our findings elucidate novel aspects of the molecular patho-
genesis associated with disease causing mutations in SPG7. We
show that this disorder is associated with mtDNA damage in the
form of multiple deletions that generate multiple respiratory
complex deficiencies in skeletal muscle. This suggests that SPG7,
like other complex diseases affecting the nervous system such as
dominant optic atrophy 1 (DOA1), is linked to the maintenance of
mitochondrial DNA. Mitochondrial DNA changes were found
with two different SPG7 mutations, the novel c.2102A.C and the
c.1047insC reported previously [20]. MtDNA abnormalities have
never been demonstrated in SPG7 and while respiratory chain
dysfunction has been found [24,25] the aetiology has been unclear.
Although multiple mtDNA deletions were clearly detected by
LPCR in both patients, quantifying them by qPCR required
analysis in single fibres. This is due to the fact that deleted mtDNA
segregated in respiratory deficient cells of which there were fewer
than 5% in the muscle biopsy. Uneven distribution of mtDNA
defects in individual muscle fibres is a common phenomenon that
has been reported with both single and multiple mtDNA deletions
[39,42].
The molecular mechanisms underlying the formation of
mtDNA deletions in SPG7 remain unclear. Multiple mtDNA
deletions commonly occur in disorders affecting either mtDNA
homeostasis directly, such as mutations of POLG and C10orf2 [38],
or mitochondrial quality control including mutations of OPA1 [43]
and MFN1 [44]. Although paraplegin is not known to be directly
associated with the mitochondrial nucleoid, it is involved in the
processing of other mitochondrial proteins. It is therefore possible
that paraplegin mutations lead to mtDNA damage and respiratory
deficiency by impairing the function of other mitochondrial
proteins involved in either mtDNA replication itself or pathways of
mitochondrial quality control.
The high levels of mtDNA deletion in COX-deficient fibres and
the fact that respiratory deficiency in muscle selectively affected all
three complexes with subunits encoded by mtDNA, but not
complex II, suggest that this is indeed caused by mtDNA damage.
Interestingly, complex I was more severely affected than III or IV.
Selective complex I deficiency is seen with other disorders of
mtDNA homeostasis including POLG and Twinkle associated
disease [38,45] and may have to do with the high number (seven)
of complex I subunits encoded in mtDNA and/or with the fact
that five of those subunits are encoded in the part of mtDNA
commonly affected by deletions.
In spite of their overall low levels in the vastus muscle, it is
possible that mtDNA deletions play an important role in the
pathogenesis of SPG7. MtDNA defects of either primary or
secondary etiology are known to segregate predominantly in
clinically affected tissues. The extraocular muscles and nervous
system, which are the primarily affected organs in this condition,
may harbour significantly higher levels of mtDNA defects, but
data from these tissues are currently unavailable. From studies
performed in other disorders such as DOA1, it has been shown
that mtDNA deletions can be found in tissue from unaffected
organs, e.g. muscle, even if the major clinical symptoms and
findings involve other organs, such as e.g. optic nerve [46,47].
We also report a novel SPG7 mutation. The c.2102A.C,
p.H 701P segregated with the clinical phenotype and was absent
in a large number of unrelated, healthy controls. This mutation
changes a highly conserved amino acid situated within a catalytic
metallopeptidase domain in paraplegin, where most of the known
pathogenic mutations occur [9]. We believe, therefore, that the
mutation is pathogenic. In silico analysis did not predict significant
changes in protein stability, but as the mutation was homozygous
(or compound heterozygous) in affected individuals, overall effects
on protein function may have been underestimated.
Ptosis [20] and ophthalmoplegia [22] have been reported
previously in SPG7. Our findings confirm that this is indeed not an
uncommon presentation of this disorder and we suggest that SPG7
gene analysis should be included in the diagnostic workup of
autosomal recessive PEO, especially if spasticity is present. PEO is
a common mitochondrial disease phenotype and associated either
with primary mtDNA mutations or mutations of nuclear genes
involved in mtDNA homeostasis, such as polymerase gamma
(POLG1 & POLG2) [48,49], C10orf2 [50], ANT1 [51], TK2 [52] and
RRM2B [53] that cause secondary mtDNA changes including
multiple deletions and/or depletion.
Our findings increase our understanding of the molecular
pathogenesis of SPG7 mutations and link paraplegin to mtDNA
homeostasis.
Supporting Information
Figure S1 The conservation score for the mutated DNA
base according to PhastCons and Genomic Evolutionary
Rate Profiling (GERP) software available at the Univer-
sity of California Santa Cruz. The mutated base and coded
amino acid in different species are highlighted by a red rectangle.
Histidine is highly conserved at the position affected by the
mutation.
(DOCX)
Figure S2 Functional studies of the novel c.2102A.C
mutation in SPG7. A: Gel electrophoresis of PCR products
obtained from cDNA of the proband (P) and two controls (C1, C2)
using primer pairs 1 (primers L2 and R1) and 2 (primers L2 and
R2) as indicated. All PCR products are of expected size, and no
additional fragments were detected. Primer information is given in
Table 1, supplementary material. B: Expression levels of SPG7 in
leucocytes from the patient (dark bars) compared with the mean of
seven controls (light bars). SPG7 expression was assessed with three
primer pairs (SPG7_1-3) and compared to three housekeeping
genes (HPRT, PPIB, HMBS).
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Table S1 A: Primers for PCR on genomic DNA and
Sanger sequencing. B: Primers for cDNA amplification to
check the splicing. C: Primers for cDNA to check the expression
level in peripheral blood.
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